Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial

Thrombosis Research

Volumn 119, Issue 1, 2007, Pages 27-34

  Schmidt Lucke, Caroline ^a   Paar, W Dieter ^b   Stellbrink, Christoph ^c   Nixdorff, Uwe ^d   Hofmann, Thomas ^e   Meurer, Jürgen ^f   Grewe, Rolf ^b   Daniel, Werner Günther ^d   Hanrath, Peter ^c   Mügge, Andreas ^g   Klein, Helmut U ^h   Schmidt Lucke, Jan André ⁱ  

^a GOETHE UNIVERSITY   (Germany)

^b Sanofi   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f Omnicare Clinical Research   (Germany)

^g ST JOSEF HOSPITAL   (Germany)

^h OTTO VON GUERICKE UNIVERSITY   (Germany)

ⁱ MARTIN LUTHER KRANKENHAUS   (Germany)

Author keywords

Atrial fibrillation; Cardioversion; Coumarins; Quality of anticoagulation; Unfractionated heparin

Indexed keywords

HEPARIN; PHENPROCOUMON;

ADULT; AGED; ANALYTIC METHOD; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; ELECTRIC COUNTERSHOCK; ENOXAPARIN; HEPARIN; HUMANS; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PHENPROCOUMON; PROSPECTIVE STUDIES; THROMBOEMBOLISM; TIME FACTORS;

EID: 33750906583     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.11.016     Document Type: Article

References (31)

1. Wolf P.A., Abbott R.D., and Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 22 (1991) 983-988
2. Miller V.T., Pearce L.A., Feinberg W.M., Rothrock J.F., Anderson D.C., and Hart R.G. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Neurology 46 (1996) 238-240
3. Hylek E.M., Skates S.J., Sheehan M.A., and Singer D.E. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335 (1996) 540-546
4. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 348 (1996) 633-638
5. Hylek E.M., Go A.S., Chang Y., Jensvold N.G., Henault L.E., Selby J.V., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349 (2003) 1019-1026
6. Fuster V., Ryden L.E., Asinger R.W., Cannom D.S., Crijns H.J., Frye R.L., et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation); North American Society of Pacing and Electrophysiology. ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 104 (2001) 2118-2150
7. Klein A.L., Grimm R.A., Murray R.D., Apperson-Hansen C., Asinger R.W., Black I.W., et al. Assessment of cardioversion using transesophageal echocardiography investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344 (2001) 1411-1420
8. Evans A., and Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice?. Arch Intern Med 161 (2001) 1443-1447
9. Gottlieb L.K., and Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice?. Arch Intern Med 154 (1994) 1945-1953
10. Caro J.J., Flegel K.M., Orejuela M.E., Kelley H.E., Speckman J.L., and Migliaccio-Walle K. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. CMAJ 161 (1999) 493-497
11. Kalra L., Yu G., Perez I., Lakhani A., and Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 320 (2000) 1236-1239
12. Stellbrink C., Hanrath P., Nixdorff U., Hofmann T., Lehmacher W., Kuhle K., et al. Anticoagulation in Cardioversion using Enoxaparin Study Group. Low molecular weight heparin for prevention of thromboembolic complications in cardioversion-rationale and design of the ACE study (Anticoagulation in Cardioversion using Enoxaparin). Z Kardiol 91 (2002) 249-254
13. Raschke R.A., Reilly B.M., Guidry J.R., Fontana J.R., and Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 119 (1993) 874-881
14. Stellbrink C., Nixdorff U., Hofmann T., Lehmacher W., Daniel W.G., Hanrath P., et al., the ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 109 (2004) 997-1003
15. Arnold A.Z., Mick M.J., Mazurek R.P., Loop F.D., and Trohman R.G. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 19 (1992) 851-855
16. Bjerkelund C., and Orning O.M. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 23 (1969) 208-216
17. Weinberg D.M., and Mancini J. Anticoagulation for cardioversion in atrial fibrillation. Am J Cardiol 63 (1989) 754-756
18. Klein A.L., Murray R.D., and Grimm R.A. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 37 (2001) 691-704
19. Blacker D.J., Wijdicks E.F., and McClelland R.L. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology 61 (2003) 964-968
20. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med 333 (1995) 5-10
21. Hylek E.M., and Singer D.E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120 (1994) 897-902
22. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 337 (1997) 688-698
23. Sobel M., McNeill P.M., Carlson P.L., Kermode J.C., Adelman B., Conroy R., et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 87 (1991) 1787-1793
24. Young E., Wells P., Holloway S., Weitz J., and Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 71 (1994) 300-304
25. Omran H., Hammerstingl C., Schmidt H., von der Recke G., Paar W.D., and Luderitz B. A prospective and randomized comparison of the safety and effects of therapeutic levels of enoxaparin versus unfractionated heparin in chronically anticoagulated patients undergoing elective cardiac catheterization. Thromb Haemost 90 (2003) 267-271
26. Collet J.P., Montalescot G., Lison L., Choussat R., Ankri A., Drobinski G., et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 103 (2001) 658-663
27. Aslam M.S., Sundberg S., Sabri M.N., Cooke D., and Lakier J.B. Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv 57 (2002) 187-190
28. Frydman A.M., Bara L., Le Roux Y., Woler M., Chauliac F., and Samama M.M. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 28 (1988) 609-618
29. Alhenc-Gelas M., Jestin-Le Guernic C., Vitoux J.F., Kher A., Aiach M., and Fiessinger J.N. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. Thromb Haemost 71 (1994) 698-702
30. Ferguson J.J., Califf R.M., Antman E.M., Cohen M., Grines C.L., Goodman S., et al., SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. Primary results of the SYNERGY randomized trial. JAMA 292 (2004) 45-54
31. Olsson S.B. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362 (2003) 1691-1698